1565nm Non-ablative Fractional Laser Treat Alopecia Areata
Alopecia Areata
About this trial
This is an interventional treatment trial for Alopecia Areata focused on measuring Alopecia Areata, 1565nm Non-ablative Fractional Laser, immune privilege
Eligibility Criteria
Inclusion Criteria: Male or female subjects aged ≥ 18 years and ≤ 55 years of age; Alopecia areata subjects, and diagnosed with alopecia areata for 6 -12 months before screening; Women of childbearing age, non-pregnant or lactating, and subjects and their partners voluntarily take contraceptive measures deemed effective by the investigator during treatment and for at least 6 months after the last trial; Those who have no contraindications to the use of materials; Subject is able to understand and voluntarily sign the written informed consent form, which must be signed prior to the execution of any trial-specified study procedures; Subjects must be voluntary and able to complete the study procedure and follow-up examination. Exclusion Criteria: Subjects who meet the diagnostic criteria for alopecia areata but are accompanied by the following diseases cannot be enrolled: local infection (bacterial, fungal or viral) at the site requiring laser treatment; Have a psychiatric disorder (e.g., schizophrenia, neurosis, organic psychosis, etc.); Subjects who have previously treated drugs or surgeries and cannot be enrolled in the following situations: receiving other anti-alopecia areata treatments (including topical glucocorticoids,microneedling, laser treatment, etc.) at the same time; Receiving any other clinical investigational drug treatment concurrently; Any other situation or condition in which the investigator considers that the subject is not suitable to participate in this study.
Sites / Locations
- Xianjie WuRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Laser group
control group
Every 3 weeks, a fixed 1 / 2 of the alopecia area was treated with a 1565-nm non-ablative fractional laser.
There was no treatment for the other half of the alopecia area in the patients.